UNITED STATES OF AMERICA v. GILEAD SCIENCES, INC.

CourtDistrict Court, E.D. Pennsylvania
DecidedMarch 31, 2022
Docket2:17-cv-01183
StatusUnknown

This text of UNITED STATES OF AMERICA v. GILEAD SCIENCES, INC. (UNITED STATES OF AMERICA v. GILEAD SCIENCES, INC.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
UNITED STATES OF AMERICA v. GILEAD SCIENCES, INC., (E.D. Pa. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

UNITED STATES, et al. ex rel. TOBY TRAVIS, Plaintiffs, CIVIL ACTION NO. 17-1183 v. GILEAD SCIENCES, INC., et al., Defendant.

ORDER AND NOW, this 31st day of March 2022, upon consideration of: (1) the Motion to Dismiss [Doc. No. 56] filed by Defendant Gilead Sciences, Inc. (“Gilead”); (2) the Request for Judicial Notice [Doc. No. 57] filed by Gilead; (3) the Motion to Dismiss (Joinder) [Doc. No. 58] filed by Defendant Good Health, Inc., d/b/a Premier Pharmacy Services (“Premier”); and (4) the associated briefing of the parties; and for the reasons set forth in the Memorandum Opinion to follow, it is hereby ORDERED that: 1. Relator’s “reverse False Claims Act” claim,1 and each derivative state law claim similarly alleging the fraudulent retention of moneys paid by government actors, is deemed voluntarily dismissed without prejudice, pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i).2 To the extent that the United States objects to this voluntary dismissal, the United States may, within 30 days of the date of this Order,

1 TAC [Doc. No. 49] ¶ 284(4). 2 Relator voluntarily dismisses these claims in response to the arguments set forth in Gilead’s motion to dismiss. See Pl.’s Resp. Opp’n Gilead’s Mot. Dismiss [Doc. No. 60] at 1 n.2. file a motion to vacate the relevant portion of this Order pursuant to paragraph 10 of this Court’s Order of December 12, 2020.3

2. The unopposed Request for Judicial Notice [Doc. No. 57] filed by Defendant Gilead Sciences, Inc. is GRANTED.

3. The Motion to Dismiss [Doc. No. 56] filed by Defendant Gilead Sciences, Inc. is GRANTED IN PART and DENIED IN PART, as follows:4 a. With respect to the following alleged violations of the False Claims Act,5 and each derivative state law claim, Gilead’s Motion to Dismiss is DENIED: i. Fraud related to Gilead’s Sovaldi and Harvoni Speaker Programs; and ii. Fraud related to Gilead’s relationship with the PAN Foundation.

3 Doc. No. 19. 4 As these claims are brought under the False Claims Act and similarly structured state laws, they sound in fraud and are subject to Federal Rule of Civil Procedure 9(b)’s pleading requirements. The purpose of the heightened pleading requirement in Rule 9(b) is to “provide defendants with fair notice of the plaintiffs’ claims,” and to “place the defendants on notice of the precise misconduct with which they are charged.” Foglia v. Renal Ventures Mgmt., LLC, 754 F.3d 153, 156 (3d Cir. 2014); Grant v. Turner, 505 F. App’x 107, 111 (3d Cir. 2012). The TAC alleges multiple theories of misconduct and categories of conduct, each of which alleges violations of the False Claims Act and implicates a separate set of underlying claims. The Court identifies the allegations concerning the specific theories or activities that are inadequately pleaded so that Defendants are not “left to guess” which alleged activities “were fraudulent, and most importantly, how those [activities] were fraudulent.” State Farm Mut. Auto. Ins. Co. v. Ficchi, No. 10-555, 2012 WL 1578247, at *7 (E.D. Pa. May 4, 2012) (dismissing certain paragraphs of a complaint alleging that certain conduct was fraudulent but failed to meet the particularity requirement of Rule 9(b)). 5 TAC [Doc. No. 79] ¶ 284(1)–(2). 2 b. With respect to the following alleged violations of the False Claims Act,6 and each derivative state law claim, Gilead’s Motion to Dismiss is GRANTED, and the following allegations of fraud are DISMISSED without prejudice: i. Fraud related to pre-approval marketing of Sovaldi and Harvoni; ii. Fraud related to off-label marketing of Sovaldi and Harvoni;

iii. Fraud related to misleading marketing of Sovaldi and Harvoni; and iv. Fraud related to F-Score manipulation. c. With respect to claims alleging conspiracy between Gilead and the PAN Foundation to violate the False Claims Act,7 and each derivative state law claim, Gilead’s Motion to Dismiss is DENIED. d. With respect to claims alleging conspiracy between Gilead and Premier to violate the False Claims Act,8 and each derivative state law claim, Gilead’s Motion to Dismiss is GRANTED, and all such claims are DISMISSED without prejudice.

e. The remainder of Gilead’s motion is DENIED.

4. The Motion to Dismiss (Joinder) [Doc. No. 58] filed by Defendant Good Health, Inc., d/b/a Premier Pharmacy Services is GRANTED as to claims alleging conspiracy

6 TAC [Doc. No. 79] ¶ 284(1)–(2). 7 TAC [Doc. No. 79] ¶ 284(3). 8 TAC [Doc. No. 79] ¶ 284(3). 3 between Gilead and Premier to violate the False Claims Act,9 and is otherwise DENIED. It is so ORDERED. BY THE COURT: /s/ Cynthia M. Rufe _____________________ CYNTHIA M. RUFE, J.

9 TAC [Doc. No. 79] ¶ 284(3). 4

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Brian Grant v. Darryl Turner
505 F. App'x 107 (Third Circuit, 2012)
Thomas Foglia v. Renal Ventures Management
754 F.3d 153 (Third Circuit, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
UNITED STATES OF AMERICA v. GILEAD SCIENCES, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-of-america-v-gilead-sciences-inc-paed-2022.